zolpidem has been researched along with Disease Models, Animal in 26 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Objective To evaluate the effects of zolpidem on functional recovery in a rat model of acute ischemic stroke." | 7.88 | Effect of zolpidem on functional recovery in a rat model of ischemic stroke. ( Chae, SW; Choi, HY; Chun, SW; Lee, YT; Oh, MK; Park, YH; Park, YS; Shin, HS; Yoon, KJ, 2018) |
| " We have now applied autoradiography to study properties of GABA(A)/benzodiazepine receptors in 9-day-old rats acutely (6 h) and sub-acutely (7 days) after kainic acid-induced status epilepticus by analyzing displacement of [(3)H]flunitrazepam binding by zolpidem, a ligand selective for the alpha1beta2gamma2 receptor subtype." | 7.74 | Status epilepticus alters zolpidem sensitivity of [3H]flunitrazepam binding in the developing rat brain. ( Holopainen, IE; Kukko-Lukjanov, TK; Laurén, HB; Lopez-Picon, FR; Uusi-Oukari, M, 2007) |
| "Objective To evaluate the effects of zolpidem on functional recovery in a rat model of acute ischemic stroke." | 3.88 | Effect of zolpidem on functional recovery in a rat model of ischemic stroke. ( Chae, SW; Choi, HY; Chun, SW; Lee, YT; Oh, MK; Park, YH; Park, YS; Shin, HS; Yoon, KJ, 2018) |
| "To clarify the effects of zolpidem, a gamma-aminobutyric acid (GABA)(A) receptor agonist, on bladder function, and urine production, we investigated the effects of zolpidem administration on bladder overactivity induced by cerebral infarction (CI) and on urine excretion increased by water overloading in Wistar rats." | 3.76 | Zolpidem increases bladder capacity and decreases urine excretion in rats. ( Matsuta, Y; Ohtake, A; Sasamata, M; Suzuki, M; Watanabe, M; Yanai-Inamura, H; Yokoyama, O, 2010) |
| " We have now applied autoradiography to study properties of GABA(A)/benzodiazepine receptors in 9-day-old rats acutely (6 h) and sub-acutely (7 days) after kainic acid-induced status epilepticus by analyzing displacement of [(3)H]flunitrazepam binding by zolpidem, a ligand selective for the alpha1beta2gamma2 receptor subtype." | 3.74 | Status epilepticus alters zolpidem sensitivity of [3H]flunitrazepam binding in the developing rat brain. ( Holopainen, IE; Kukko-Lukjanov, TK; Laurén, HB; Lopez-Picon, FR; Uusi-Oukari, M, 2007) |
| "Insomnia is a common and disabling complaint for which there is a need for improved treatments." | 2.73 | A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2007) |
| "Papaverine and zolpidem were recently shown to be protective of bioenergetic loss in cell models of optic neuropathy." | 1.46 | Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules. ( Cortopassi, GA; Datta, S; McMackin, MZ; Yu, AK, 2017) |
| "Tauopathies are also associated with deficits in synaptic plasticity such as long-term potentiation (LTP), but the specific role of tau in the manifestation of these deficiencies is not well-understood." | 1.39 | Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. ( Cain, P; Franke, TF; Hoeffer, CA; Krishnamurthy, P; Levenga, J; Rajamohamedsait, H; Sigurdsson, EM; Wong, H, 2013) |
| "Spinocerebellar ataxias are autosomal dominant diseases, associated in some types with a CAG repeat expansion, and characterised by a progressive loss of motor function." | 1.39 | Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1. ( Nag, N; Storey, E; Tarlac, V, 2013) |
| "Zolpidem is a widely used hypnotic drug acting via benzodiazepine binding sites on GABA(A) receptors." | 1.36 | Zolpidem is a potent anticonvulsant in adult and aged mice. ( Pericić, D; Vlainić, J, 2010) |
| " Following recovery, animals were dosed with caffeine (10 mg/kg) alone or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg)." | 1.35 | Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 12 (46.15) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Keenan, RJ | 1 |
| Daykin, H | 1 |
| Chu, J | 1 |
| Cornthwaite-Duncan, L | 1 |
| Allocca, G | 1 |
| Hoyer, D | 1 |
| Jacobson, LH | 1 |
| Schreiber, S | 1 |
| Pick, CG | 1 |
| Oh, MK | 1 |
| Yoon, KJ | 1 |
| Lee, YT | 1 |
| Chae, SW | 1 |
| Choi, HY | 1 |
| Shin, HS | 1 |
| Park, YH | 1 |
| Chun, SW | 1 |
| Park, YS | 1 |
| Yu, AK | 1 |
| Datta, S | 1 |
| McMackin, MZ | 1 |
| Cortopassi, GA | 1 |
| Levenga, J | 1 |
| Krishnamurthy, P | 1 |
| Rajamohamedsait, H | 1 |
| Wong, H | 1 |
| Franke, TF | 1 |
| Cain, P | 1 |
| Sigurdsson, EM | 1 |
| Hoeffer, CA | 1 |
| El Zahaf, NA | 1 |
| Salem Elhwuegi, A | 1 |
| Han, S | 1 |
| Tai, C | 1 |
| Jones, CJ | 1 |
| Scheuer, T | 1 |
| Catterall, WA | 1 |
| Auta, J | 1 |
| Impagnatiello, F | 1 |
| Kadriu, B | 1 |
| Guidotti, A | 1 |
| Costa, E | 1 |
| Paterson, LM | 2 |
| Wilson, SJ | 2 |
| Nutt, DJ | 2 |
| Hutson, PH | 2 |
| Ivarsson, M | 2 |
| Kozell, LB | 1 |
| Walter, NA | 1 |
| Milner, LC | 1 |
| Wickman, K | 1 |
| Buck, KJ | 1 |
| Yokoyama, O | 1 |
| Matsuta, Y | 1 |
| Yanai-Inamura, H | 1 |
| Watanabe, M | 1 |
| Ohtake, A | 1 |
| Suzuki, M | 2 |
| Sasamata, M | 1 |
| Vlainić, J | 2 |
| Pericić, D | 2 |
| Heldt, SA | 1 |
| Ressler, KJ | 1 |
| Hambrecht-Wiedbusch, VS | 1 |
| Gauthier, EA | 1 |
| Baghdoyan, HA | 1 |
| Lydic, R | 1 |
| Narita, M | 2 |
| Niikura, K | 1 |
| Nanjo-Niikura, K | 1 |
| Furuya, M | 1 |
| Yamashita, A | 1 |
| Saeki, M | 1 |
| Matsushima, Y | 1 |
| Imai, S | 1 |
| Shimizu, T | 1 |
| Asato, M | 1 |
| Kuzumaki, N | 1 |
| Okutsu, D | 1 |
| Miyoshi, K | 1 |
| Tsukiyama, Y | 1 |
| Konno, M | 1 |
| Yomiya, K | 1 |
| Matoba, M | 1 |
| Suzuki, T | 1 |
| Nag, N | 1 |
| Tarlac, V | 1 |
| Storey, E | 1 |
| Zanin, KA | 1 |
| Patti, CL | 1 |
| Sanday, L | 1 |
| Fernandes-Santos, L | 1 |
| Oliveira, LC | 1 |
| Poyares, D | 1 |
| Tufik, S | 1 |
| Frussa-Filho, R | 1 |
| Rode, F | 1 |
| Jensen, DG | 1 |
| Blackburn-Munro, G | 1 |
| Bjerrum, OJ | 1 |
| Mathiasen, L | 1 |
| Mirza, NR | 1 |
| Laurén, HB | 1 |
| Lopez-Picon, FR | 1 |
| Kukko-Lukjanov, TK | 1 |
| Uusi-Oukari, M | 1 |
| Holopainen, IE | 1 |
| Strac, DS | 1 |
| Mangan, PS | 1 |
| Bertram, EH | 1 |
| Defazio, RA | 2 |
| Hablitz, JJ | 2 |
1 trial available for zolpidem and Disease Models, Animal
| Article | Year |
|---|---|
A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers.
Topics: Adult; Animals; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Disease Models, Ani | 2007 |
25 other studies available for zolpidem and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Differential sleep/wake response and sex differences following acute suvorexant, MK-1064 and zolpidem administration in the rTg4510 mouse model of tauopathy.
Topics: Animals; Azepines; Disease Models, Animal; Female; Hypnotics and Sedatives; Male; Mice; Mice, Transg | 2022 |
Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep?
Topics: Analgesics; Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Disease Models, Animal; | 2020 |
Effect of zolpidem on functional recovery in a rat model of ischemic stroke.
Topics: Animals; Brain Ischemia; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Drug Administrat | 2018 |
Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules.
Topics: Animals; Disease Models, Animal; DNA, Mitochondrial; Electron Transport Complex I; Glaucoma, Open-An | 2017 |
Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments.
Topics: Animals; Cell Count; Cerebral Cortex; Disease Models, Animal; GABA-A Receptor Agonists; GABAergic Ne | 2013 |
The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice.
Topics: Alprazolam; Animals; Depression; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
Enhancement of inhibitory neurotransmission by GABAA receptors having α2,3-subunits ameliorates behavioral deficits in a mouse model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Benzodiazepines; Brain; Disease Models, Animal; Fluoro | 2014 |
Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem.
Topics: Animals; Anticonvulsants; Behavior, Animal; Benzodiazepines; Bicuculline; Diazepam; Differential Thr | 2008 |
Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption.
Topics: Animals; Body Temperature; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Elec | 2009 |
Mapping a barbiturate withdrawal locus to a 0.44 Mb interval and analysis of a novel null mutant identify a role for Kcnj9 (GIRK3) in withdrawal from pentobarbital, zolpidem, and ethanol.
Topics: Animals; Area Under Curve; Behavior, Animal; Brain; Chromosome Mapping; Chromosomes, Human, Pair 1; | 2009 |
Zolpidem increases bladder capacity and decreases urine excretion in rats.
Topics: Aldosterone; Animals; Bicuculline; Cerebral Infarction; Disease Models, Animal; Dose-Response Relati | 2010 |
Zolpidem is a potent anticonvulsant in adult and aged mice.
Topics: Age Factors; Aging; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interact | 2010 |
Amygdala-specific reduction of alpha1-GABAA receptors disrupts the anticonvulsant, locomotor, and sedative, but not anxiolytic, effects of benzodiazepines in mice.
Topics: Amygdala; Animals; Animals, Newborn; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Cell Lin | 2010 |
Benzodiazepine receptor agonists cause drug-specific and state-specific alterations in EEG power and acetylcholine release in rat pontine reticular formation.
Topics: Acetylcholine; Animals; Azabicyclo Compounds; Brain; Diazepam; Disease Models, Animal; Dose-Response | 2010 |
Sleep disturbances in a neuropathic pain-like condition in the mouse are associated with altered GABAergic transmission in the cingulate cortex.
Topics: Analysis of Variance; Animals; Anisoles; Disease Models, Animal; Electroencephalography; Electromyog | 2011 |
Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.
Topics: Amantadine; Animals; Ataxin-1; Ataxins; Buspirone; Disease Models, Animal; Dopamine Agents; Genotype | 2013 |
Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Discrimination Learning; Disease Models, Ani | 2013 |
Centrally-mediated antinociceptive actions of GABA(A) receptor agonists in the rat spared nerve injury model of neuropathic pain.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; GABA Agonists; GABA-A | 2005 |
A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiazepinones; Chlordiazepoxide; Confli | 2005 |
Status epilepticus alters zolpidem sensitivity of [3H]flunitrazepam binding in the developing rat brain.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Autoradiography; Brain; Disease Models | 2007 |
Sedative and anticonvulsant effects of zolpidem in adult and aged mice.
Topics: Age Factors; Animals; Anticonvulsants; Brain; Convulsants; Diazepam; Disease Models, Animal; Dose-Re | 2008 |
Shortened-duration GABA(A) receptor-mediated synaptic potentials underlie enhanced CA1 excitability in a chronic model of temporal lobe epilepsy.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Disea | 1997 |
Reduction of zolpidem sensitivity in a freeze lesion model of neocortical dysgenesis.
Topics: Animals; Disease Models, Animal; Electric Stimulation; Electrophysiology; Excitatory Postsynaptic Po | 1999 |
Altered receptor subunit expression in rat neocortical malformations.
Topics: Animals; Disease Models, Animal; Epilepsy; Excitatory Postsynaptic Potentials; Freezing; Neocortex; | 2000 |